The latest policies, articles, white papers, and more.
The RAPIDS Network Quality Measures Working Group convened to recommend new quality measures that capture previous gaps in antimicrobial stewardship and infection prevention & control data collection and measurement.
Among the measures that were recommended for revision, the group identified those in the Value-Based Purchasing (VBP) program that may result in inappropriate penalization and should therefore be temporarily removed while undergoing revision or replacement, with continued inclusion in the Hospital Inpatient Quality Reporting (IQR) program.
The RAPIDS Network believes that increased interoperability can strike the balance between the important need for reporting public health data to Federal, State, and local officials and the administrative burden that falls on health systems to do so.
The RAPIDS (Regulation And Policy for Infectious Disease Stewardship) Network is co-convened by Rubrum Advising, the Federation of American Hospitals (FAH), and the Association of American Medical Colleges (AAMC). Members include a variety of infectious disease stakeholders whose goal is to improve the quality of care for patients in hospitals through the enhancement of Antimicrobial Stewardship Programs (ASPs).
Rubrum Advising, a fast-growing health policy, regulatory, and market access firm, today announced Tamara Syrek Jensen, JD, has joined the firm as Vice President of Federal Programs.
Two years in, Rubrum Advising’s North Star remains clear: helping patients access meaningful, high-impact care by aligning innovation with the clinical knowledge, regulatory frameworks, and policy trends that deliver it.
Rubrum Advising, a boutique firm rooted in clinical practice and dedicated to developing healthcare market access, regulatory and policy strategies that demonstrate the value of groundbreaking innovations to payers and providers, today announced the launch of a new government affairs and advocacy practice.
The Alliance for Screening Measurement Modernization (ASMM) brings together organizations from across the healthcare sector to explore a broader framework for the timely integration of evidence into currently endorsed national health screening policies.
In the U.S., a significant barrier to ensuring high quality health care is our very complex regulatory environment. As the pace of innovation continues increasing rapidly, it is critical that our policy infrastructure evolves to meet the moment.
The dispute between the FDA and clinical laboratories over the agency’s efforts to regulate LDTs (laboratory developed tests) has focused on the question of authority: does the FDA’s authority to regulate devices include LDTs?
Rubrum Advising